NRG Therapeutics Ltd., focused on neuroscience, secured a £50 million (approximately $67 million) Series B funding to advance preclinical development of novel small molecules modulating the mitochondrial permeability transition pore. This class of therapeutics aims to address mechanisms implicated in amyotrophic lateral sclerosis (ALS), with clinical testing anticipated to begin next year. Investors include venture arms of Merck KGaA and Novartis, highlighting robust interest in neurodegenerative disease innovation.